tetano
Editor, Senior Moderator
Sci Rep
. 2023 Mar 18;13(1):4482.
doi: 10.1038/s41598-023-31544-5.
Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
Luís Coelho[SUP] 1 2 [/SUP], Fatima Falcão[SUP] 3 4 [/SUP], Pedro Póvoa[SUP] 5 6 7 [/SUP], Erica Viegas[SUP] 3 4 [/SUP], Antonio Pais Martins[SUP] 8 [/SUP], Eduarda Carmo[SUP] 9 [/SUP], Candida Fonseca[SUP] 6 10 [/SUP], Luis Campos[SUP] 6 10 [/SUP], Kamal Mansinho[SUP] 6 11 [/SUP], Inês Carmo[SUP] 3 [/SUP], Joana Soares[SUP] 3 [/SUP], Mariana Solano[SUP] 3 [/SUP], Dina Mendes[SUP] 3 [/SUP], Ana Cláudia Miranda[SUP] 11 [/SUP], Antonio Carvalho[SUP] 10 12 [/SUP], Ana Mirco[SUP] 4 12 [/SUP], Helena Farinha[SUP] 4 12 [/SUP], Isabel Aldir[SUP] 6 11 12 [/SUP], José Correia[SUP] 12 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.
. 2023 Mar 18;13(1):4482.
doi: 10.1038/s41598-023-31544-5.
Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
Luís Coelho[SUP] 1 2 [/SUP], Fatima Falcão[SUP] 3 4 [/SUP], Pedro Póvoa[SUP] 5 6 7 [/SUP], Erica Viegas[SUP] 3 4 [/SUP], Antonio Pais Martins[SUP] 8 [/SUP], Eduarda Carmo[SUP] 9 [/SUP], Candida Fonseca[SUP] 6 10 [/SUP], Luis Campos[SUP] 6 10 [/SUP], Kamal Mansinho[SUP] 6 11 [/SUP], Inês Carmo[SUP] 3 [/SUP], Joana Soares[SUP] 3 [/SUP], Mariana Solano[SUP] 3 [/SUP], Dina Mendes[SUP] 3 [/SUP], Ana Cláudia Miranda[SUP] 11 [/SUP], Antonio Carvalho[SUP] 10 12 [/SUP], Ana Mirco[SUP] 4 12 [/SUP], Helena Farinha[SUP] 4 12 [/SUP], Isabel Aldir[SUP] 6 11 12 [/SUP], José Correia[SUP] 12 [/SUP]
Affiliations
- PMID: 36934143
- DOI: 10.1038/s41598-023-31544-5
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7-12.8; 14.9-17.1; p = .016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients.